Septerna drops lead asset over bilirubin side effects 4 months after going public
Septerna stood out from the crowd of biotech IPOs last year due to the lack of clinical data to hand. Now, the data are coming in—and it’s led the biotech to abandon its lead asset.
Septerna stood out from the crowd of biotech IPOs last year due to the lack of clinical data to hand. Now, the data are coming in—and it’s led the biotech to abandon its lead asset.
